The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Oncology Report

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/OR_00000998PMID 20878136
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

  2008cited by this paper
• Antiandrogen withdrawal in castrate‐refractory prostate cancer

  2008cited by this paper
• Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR

  2007cited by this paper
• Androgen and anti‐androgen treatment modulates androgen receptor activity and DJ‐1 stability

  2006cited by this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cited by this paper
• Controversies of androgen ablation therapy for metastatic prostate cancer.

  2006cited by this paper
• Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review

  2006cited by this paper
• Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.

  2005cited by this paper
• Structural basis for antagonism and resistance of bicalutamide in prostate cancer

  2005cited by this paper
• Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancer

  2005cited by this paper
• Androgen Receptor Cross-talk with Cell Signalling Pathways

  2004cited by this paper
• Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

  2003cited by this paper
• Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.

  2002cited by this paper
• Erratum: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor (Nature Medicine (2000) 6 (703-706))

  2000cited by this paper
• Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3'-kinase pathway.

  2000cited by this paper
• Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

  2000cited by this paper
• Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

  1997cited by this paper
• Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.

  1993cited by this paper
• A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

  1990cited by this paper

• Study of Glabranin as an Inhibitor Against Prostate Cancer: Molecular Docking, Molecular Dynamics Simulation, MM-PBSA Calculation and QSAR Prediction

  2023cites this paper
• Computational approaches for evaluation of isobavachin as potential inhibitor against t877a and w741l mutations in prostate cancer

  2022cites this paper
• Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation

  2020cites this paper
• Prostate Neoplasm

  2019cites this paper
• Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.

  2018cites this paper
• Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer.

  2018cites this paper
• Knowledge-Guided Prioritization of Genes Determinant of Drug Response using ProGENI

  2016influential citation
• Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

  2016cites this paper
• Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells.

  2016cites this paper
• Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance

  2016cites this paper
• Current world literature.

  2012cites this paper
• Biology of castration-recurrent prostate cancer.

  2012cites this paper